86 related articles for article (PubMed ID: 12447996)
21. Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.
Zannetti A; Del Vecchio S; Romanelli A; Scala S; Saviano M; Cali' G; Stoppelli MP; Pedone C; Salvatore M
Biochem Pharmacol; 2005 Nov; 70(9):1277-87. PubMed ID: 16143315
[TBL] [Abstract][Full Text] [Related]
22. Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
Annis MG; Ouellet V; Rennhack JP; L'Esperance S; Rancourt C; Mes-Masson AM; Andrechek ER; Siegel PM
Breast Cancer Res; 2018 Jan; 20(1):9. PubMed ID: 29382358
[TBL] [Abstract][Full Text] [Related]
23. Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231.
Kozlova N; Samoylenko A; Drobot L; Kietzmann T
Mol Carcinog; 2016 Feb; 55(2):170-81. PubMed ID: 25641046
[TBL] [Abstract][Full Text] [Related]
24. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
25. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Taniguchi T; Kakkar AK; Tuddenham EG; Williamson RC; Lemoine NR
Cancer Res; 1998 Oct; 58(19):4461-7. PubMed ID: 9766679
[TBL] [Abstract][Full Text] [Related]
26. Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways.
Degryse B; Orlando S; Resnati M; Rabbani SA; Blasi F
Oncogene; 2001 Apr; 20(16):2032-43. PubMed ID: 11360187
[TBL] [Abstract][Full Text] [Related]
27. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
28. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
[TBL] [Abstract][Full Text] [Related]
30. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
[TBL] [Abstract][Full Text] [Related]
31. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
32. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
Bruckner A; Filderman AE; Kirchheimer JC; Binder BR; Remold HG
Cancer Res; 1992 Jun; 52(11):3043-7. PubMed ID: 1375533
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions.
Carriero MV; Franco P; Gargiulo L; Vocca I; Cito L; Fontana L; Iaccarino C; Del Pozzo G; Guardiola J; Stoppelli MP
Biol Chem; 2002 Jan; 383(1):107-13. PubMed ID: 11928806
[TBL] [Abstract][Full Text] [Related]
34. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Del Vecchio S; Stoppelli MP; Carriero MV; Fonti R; Massa O; Li PY; Botti G; Cerra M; D'Aiuto G; Esposito G
Cancer Res; 1993 Jul; 53(13):3198-206. PubMed ID: 7686450
[TBL] [Abstract][Full Text] [Related]
35. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Jankun J; Merrick HW; Goldblatt PJ
J Cell Biochem; 1993 Oct; 53(2):135-44. PubMed ID: 8227186
[TBL] [Abstract][Full Text] [Related]
36. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Belkacemi L; Lam E; Caldwell JD; Siemens DR; Graham CH
Exp Cell Res; 2006 Jun; 312(10):1685-92. PubMed ID: 16564525
[TBL] [Abstract][Full Text] [Related]
37. Adhesion and migration of extracellular matrix-stimulated breast cancer.
Bartsch JE; Staren ED; Appert HE
J Surg Res; 2003 Mar; 110(1):287-94. PubMed ID: 12697413
[TBL] [Abstract][Full Text] [Related]
38. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Schlechte W; Brattain M; Boyd D
Cancer Commun; 1990; 2(5):173-9. PubMed ID: 2164413
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
40. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]